Investigation of Enzalutamide, Docetaxel, and Cabazitaxel Resistance in the Castration Resistant Prostate Cancer Cell Line C4 Using Genome-Wide CRISPR/Cas9 Screening

To identify genes that modulated treatment response to these drugs, the authors performed three genome-wide CRISPR/Cas9 knockout screens in the metastatic CRPC cell line C4.